141629-19-8

Basic information

• Product Name: (4S)-4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-2-pyrrolidinone
• Synonyms: 2-Pyrrolidinone, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, (4S)-;(4S)-4-[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]-2-PYRROLIDINONE;(S)-4-(t-ButyldiMethylsilyloxy)pyrrolidin-2-one
• CAS NO: 141629-19-8
• Molecular Formula: C₁₀H₂₁NO₂Si
• Molecular Weight: 215.36
• Product Categories: Pyrrolidinone derivatives;Drug Intermediates
• Mol File: 141629-19-8.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 289.999 °C at 760 mmHg
• Flash Point: 129.187 °C
• Appearance: /
• Density: 0.965g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.455
• CAS DataBase Reference: (4S)-4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-2-pyrrolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-2-pyrrolidinone(141629-19-8)
• EPA Substance Registry System: (4S)-4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-2-pyrrolidinone(141629-19-8)

Safety Data

• Hazardous Substances Data: 141629-19-8(Hazardous Substances Data)

Usage

General Description

(4S)-4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-2-pyrrolidinone, also known as t-BuMe2Si(OTBDMS)2Pyr, is a chemical compound commonly used as a protecting group for alcohols and amines in organic synthesis. It is a derivative of 2-pyrrolidinone, with a tert-butyldimethylsilyloxy group attached to the 4-position of the pyrrolidinone ring. (4S)-4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-2-pyrrolidinone serves as a versatile and stable protecting group due to its ease of installation and removal under mild conditions, making it suitable for a wide range of synthetic applications. It is also known for its compatibility with a variety of functional groups and its ability to be selectively removed in the presence of other protecting groups, making it a valuable tool in the field of organic chemistry.

InChI:InChI=1/C10H21NO2Si/c1-10(2,3)14(4,5)13-8-6-9(12)11-7-8/h8H,6-7H2,1-5H3,(H,11,12)/t8-/m0/s1

Upstream product

• 237768-62-6 (S)-4-azido-3-(tert-butyldimethylsiloxy)butyraldehyde 
• 68108-18-9 (4S)-4-hydroxypyrrolidin-2-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 237768-61-5 ethyl (S)-4-azido-3-(tert-butyldimethylsiloxy)butanoate 

Downstream Products

• 68108-18-9 (4S)-4-hydroxypyrrolidin-2-one 
• 186428-91-1 (S)-N-benzyl-4-tert-butyldimethylsilyloxy-pyrrolidin-2-one 
• 886978-74-1 (4S)-4-{[t-butyl(dimethyl)silyl]oxy}-1-({5-[4-(ethylsulfonyl)phenoxy]-2-(2-pyridinyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazol-6-yl}methyl)pyrrolidin-2-one 
• 886978-75-2 (4S)-4-{[t-butyl(dimethyl)silyl]oxy}-1-({6-[4-(ethylsulfonyl)phenoxy]-2-(2-pyridinyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazol-5-yl}methyl)pyrrolidin-2-one 

Relevant articles and documents

Synthesis of nature product kinsenoside analogues with anti-inflammatory activity

Kinsenoside is the major bioactive component from herbal medicine with a broad range of pharmacological functions. Goodyeroside A, an epimer of kinsenoside, remains less explored. In this report we chemically synthesized kinsenoside, goodyeroside A and their analogues with glycan variation, chirality inversion at chiral center(s), and bioisosteric replacement of lactone with lactam. Among these compounds, goodyeroside A and its mannosyl counterpart demonstrated superior anti-inflammatory efficacy. Furthermore, goodyeroside A was found to suppresses inflammatory through inhibiting NF-κB signal pathway, effectively. Structure-activity relationship is also explored for further development of more promising kinsenoside analogues as drug candidates.

Method for preparing intelligence-improving medicine (S)-oxiracetam

The invention discloses a method for preparing an intelligence-improving medicine (S)-oxiracetam. The method comprises the following steps: (1) under the catalysis of 4-dimethylaminopyridine, enabling 2-oxiraneisobutylacetate to contact with ammonia gas to react, so as to obtain (S)-4-hydroxyl-2-oxopyrrolidine; (2) enabling the (S)-4-hydroxyl-2-oxopyrrolidine obtained by the step (1) to react with tert-butyldimethylsilyl chloride, so as to obtain a compound shown as a formula III, which is protected by tert-butyl dimethylsilane; (3) enabling the compound shown as the formula III and 2-bromoacetic ester to be subjected to a nucleophilic reaction under an alkaline condition, so as to obtain a compound shown as a formula IV; (4) under the catalysis of ammonium chloride, enabling the compound shown as the formula IV and ammonia gas to be subjected to an ammonolysis reaction, so as to obtain the (S)-oxiracetam as shown in the description. The (S)-oxiracetam prepared by the method provided by the invention is high in yield, high in ee value and relatively low in cost, and a preparation process is simple and is suitable for industrial production.

NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The object of the present invention is to provide a compound having a glucokinase-activating effect. A pharmaceutical composition comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein X means a nitrogen atom or CR6, wherein R6 means a hydrogen atom or a halogen atom; R1 means a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 alkylthio group; R2 means a hydrogen atom or a fluorine atom; R3 means a hydrogen atom or a C1-C6 alkyl group; and one of R4 and R5 means a hydrogen atom or a C1-C6 alkyl group, and the other means a C1-C6 alkylenecarboxylic acid, a C1-C6 alkylsulfonyl group, a C1-C6 alkylcarbonyl group, or CONH2.